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As a result of advances in treatment of childhood cancer about 75% of the affected children 
and adolescents become long-term survivors. It has been estimated that in the United States 
by the year 2010, one of 250 adults will be a long-term survivor of childhood cancer. 
The successful treatment of childhood cancer using combinations of chemotherapy, surgery 
and radiotherapy may be associated with significant morbidity and mortality in later life. 
Unlike the adult, the growing child tolerates the acute side effects of therapy relatively well. 
However, the use of cancer therapy at an early age can produce complications that may not 
become apparent until years later as the child matures or has become an adult. The treatment 
varies from one type of cancer to another. Late effects will also vary and depend largely on 
the type of therapy received and the doses of that therapy. The very young child may be at 
greatest risk. 
 
Subsequent Mortality 
Recent large epidemiological studies have analysed the subsequent mortality and its causes in 
children and adolescents, who survived 5 years from the diagnosis of cancer. Two landmark 
studies by Mertens et al. and Möller et al. published in the Journal of Clinical Oncology in 
2001 found that 5-year survivors of childhood and adolescent cancer have a standardized 
mortality ratio (SMR) of 10.8 or in other words, a 10.8-fold increased risk of death in the 
subsequent years when compared with age and sex-specific expected rates for the general 
population. The American study described a cohort of 20 227 five-year survivors of cancer 
diagnosed between 1970 and 1986 before the age of 21. The risk of death in this cohort was 
statistically higher in females (SMR 18.2) and individuals diagnosed with cancer before the 
age of 5 years (SMR 14.0). The leading cause of death was recurrence of the original cancer 
accounting for 67% of all deaths and more common between five and nine years after 
diagnosis, while treatment-related causes accounted for 21% of all deaths, of which 12.7% 
due to a second cancer, 4.5% due to cardiac and 1.8% due to pulmonary toxicity. 
 
Long-term Morbidity 
Some small and one large study have assessed the long-term morbidity that follows the 
treatment of childhood cancer. The incidence and severity of chronic health conditions in  
10,397 adults who received a diagnosis of childhood cancer between 1970 and 1986 were 
studied by Oeffinger et al. and published in the New England Journal of Medicine in 2006. 
Among the adult survivors, 62.3% had at least one chronic condition; 27.5% had a severe or 
life-threatening condition. 30 years after the cancer diagnosis, the cumulative incidence of a 
chronic health condition reached 73.4%; 42.4% for severe, disabling, or life-threatening 
conditions or death due to a chronic condition. The risk of chronic health conditions is high, 
particularly for second cancers, cardiovascular disease, renal dysfunction, severe musculo-
skeletal problems and endocrinopathies. The incidence increases over time and does not 
appear to plateau. Three groups were at highest risk: survivors of bone tumors, CNS tumors 
and Hodgkin’s disease. Survivors of these tumors were also more likely to have multiple 
conditions. In the 1970s, effective treatment for osteosarcoma of the limbs generally included 
amputation. Even with modern limb-sparing procedures, the life-altering musculoskeletal 
morbidity faced by bone-tumor survivors is clinically significant and will increase as weight-
bearing joints age more rapidly. Survivors of CNS tumors, who often have significant 
cognitive, visual, and auditory impairment and endocrinopathies, are the group most likely to 
be functionally impaired. Hodgkin’s disease survivors have the highest risk of second cancers 
and heart disease. 
Five treatment combinations were associated with an at least 10-fold increased risk of severe 
or life-threatening conditions : chest radiation plus bleomycin, chest radiation plus an 
anthracycline, chest radiation plus abdominal or pelvic irradiation, an anthracycline plus an 
alkylating agent and abdominal or pelvic irradiation plus an alkylating agent. An increase in 
cumulative dose of an alkylating agent was associated with an increased risk of any condition. 
In contrast, an increase in the cumulative dose of an anthracycline was not associated with an 
increased risk of any condition that was listed. 
As compared with men, women who survive childhood cancer have been reported to have a 
greater risk of diminished health status, second cancers, anthracycline-related cardiomyopathy 
and congestive heart failure, and cranial radiation-related cognitive dysfunction, growth 
hormone deficiency and obesity. 
When interpreting the findings of this study, it is important to keep in mind that the conditions 
were self-reported without external verification, with exception of second cancers and death. 
Several key chronic conditions such as late-onset cardiomyopathy associated with anthra-
cycline exposure, may remain clinically silent for long periods before becoming clinically 
apparent. Other conditions that may be underreported are osteoporosis, hypertension and 
insuline resistance. 
 
Complications by organ system 
The degree of abnormalities relating to each system depends on the specific modality used 
and the total dose administered. Although most organ systems are affected by radiotherapy 
and chemotherapy, the musculoskeletal and endocrine systems are most affected by the use of 
radiotherapy. Only the most frequent complications are discussed below. 
 
Musculoskeletal System 
Bone and Soft Tissue 
The higher the radiation dose (total and fractional) and the younger the patient, the more 
pronounced are the late effects. When radiotherapy impairs bone growth it can cause leg-
length discrepancy, scoliosis and short stature. The patients most affected are those treated 
before puberty with high-dose, large-volume radiotherapy, followed by patients treated with 
the same modality during puberty. 
Teeth and Salivary Glands 
Patients treated with high-dose radiation to the head and neck area are predisposed to poor 
enamel and root formation (especially of the premolars). Radiotherapy can also produce a dry 
mouth secondary to salivary gland dysfunction. 
 
Cardiopulmonary System 
Cardiac 
The potential cardiac complications are multiple and related to the use of chemotherapy, 
radiotherapy or both. In particular, patients treated with anthracyclines are at risk for the 
development of a cardiomyopathy associated with congestive heart failure. The risk increases 
dramatically with cumulative doses of over 550 mg/m2, but in children most frequently 
occurs with doses between 400 and 550 mg/m2. The risk is also related to the patient’s age 
and is approximately 1.5% in patients under 15 years of age when cumulative doses are below 
400 mg/m2. There has been increasing concern that even treatment with lower doses places 
children once adults at increased risk. The extent of cardiac complications associated with the 
use of anthracyclines in pediatric patients, the clinical significance and the risk factors for 
cardiotoxicity are not yet completely understood. Radiotherapy to the mediastinum can also 
injure the myocardium, and when combined with anthracylines, it can potentiate 
cardiotoxicity even at relatively low cumulative doses.  
Other cardiac complications seen with radiotherapy include valvular heart disease and 
premature atherosclerosis, with an increased risk of coronary artery disease and acute 
myocardial infarction, the risk directly related to the use of high-dose radiotherapy (> 30 Gy) 
at an early age. 
Pulmonary 
Bleomycin can cause pulmonary toxicity and the carbon monoxide diffusing capacity is an 
accurate predictor of subclinical toxicity. In addition, radiotherapy can cause pulmonary 
complications including paramediastinal fibrosis, pulmonary function abnormalities and 
radiation pneumonitis. Radiotherapy also potentiates the pulmonary toxicity of bleomycin.  
 
Genitourinary Complications 
Renal 
The occurrence and severity of genitourinary complications are related to the cumulative dose 
of drugs administered and to the concomitant use of radiotherapy. Ifosfamide, carboplatin and 
cisplatin can produce renal complications. These include acute tubular dysfunction manifested 
by increased excretion of potassium, phosphorus and magnesium. The tubular defect is not 
always reversible. Chronic administration of cisplatin and ifosfamide can lead to glomerular 
dysfunction including renal failure. 
Bladder 
Patients treated with radiotherapy to the pelvis can develop bladder fibrosis with a small 
bladder capacity and a predisposition to urinary tract infections. 
 
Endocrine Complications 
Pituitary 
Radiation can produce deficiency of growth hormone or other hypothalamic or pituitary 
hormones. The most common appears to be growth hormone deficiency which occurs in up to 
80% of patients treated with cranial radiotherapy for brain tumors or leukemia. The degree of 
injury is related to the total dose and fractionation schedule. Patients with leukaemia treated 
with prophylactic cranial irradiation to 2400 cGy have varying degrees of damage, depending 
on the fractional doses, the injury can also be partial. 
Females with ALL treated with prophylactic cranial irradiation tend to develop puberty 
earlier. The risk of precocious puberty is increased in girls and boys with brain tumors treated 
with high-dose radiotherapy. Most patients with precocious puberty have concomitant growth 
hormone deficiency. Another more common consequence of high-dose cranial radiotherapy is 
gonadotropin deficiency with either primary or secondary amenorrhea occurring in up to one 
third of patients receiving doses between 3000 en 6000 cGy. 
Thyroid 
The most common abnormality reported after radiotherapy to the neck area is hypothyroidism 
which can be clinical or subclinical and only detected by the presence of elevated TSH with 
normal FT4. Subclinical hypothyroidism is detected in up to two thirds of patients treated 
with mantle radiotherapy for Hodgkin’s disease. The risk is related to the total dose with an 
increased risk in children receiving more than 2600 cGy. Other complications associated with 
the use of radiotherapy include thyroid nodules, hyperthyroidism or thyroid cancer. 
Patients treated with cranial irradiation for brain tumors are also at risk for hypothyroidism. 
Gonads 
The possible late effects on the gonads are discussed in a separate topic. 
 
Neurologic System 
Central Nervous System 
Neurocognitive defects are an accepted consequence of the use of cranial radiotherapy and are 
related to the dose and the patient’s age at the time of treatment. These defects are more 
severe in patients receiving higher doses and in younger children. One third to one half of 
children treated with surgery and irradiation for brain tumours will have a subnormal IQ and 
35% of children with leukemia under 5 years of age treated with prophylactic cranial 
irradiation will develop learning disabilities. Also at increased risk are those children who 
develop a meningeal leukemic relapse and require more than one course of cranial or 
craniospinal irradiation. Other potential neurologic complications of radiotherapy include 
radiation necrosis, cerebrovascular accidents and microangiopathy. Radiation necrosis is rare 
(especially with doses under 6000 cGy). Cerebrovascular accidents most commonly manifest 
as hemiparesis, aphasia and other stroke-related symptoms and are also rare complications. 
Neurocognitive sequelae from the use of chemotherapy have become more evident with the 
routine use of increasing doses and combined modality regimens. Originally neurocognitive 
deficits were reported to spare patients treated with systemic and intrathecal methotrexate and 
no cranial irradiation. More recently, however, various studies have described neurocognitive 
impairment in children treated with higher doses of systemic and intrathecal methotrexate. 
Although IQ scores remained stable, arithmetic achievement declined significantly as well as 
patient’s verbal fluency and visual motor skills. 
Sensory Nervous System 
Chronic administration of cisplatin can result in a dose-related hearing loss occurring most 
frequently with doses in excess of 400 mg/m2 and mostly irreversible. Radiotherapy in 
combination with cisplatin will potentiate the hearing loss.  
The lens is the most radiosensitive structure within the eye and posterior subcapsular cataract 
is the characteristic late complication of radiotherapy. Cataracts with visual impairment occur 
in about 90% of patients treated with local radiotherapy for orbital rhabdomyosarcoma. 
 
Second Malignancies 
Survivors of childhood cancer are at a 10-fold increased risk of developing a second primary 
cancer compared to the general population with an estimated cumulative incidence of 3.2% at 
20-year follow-up. However the absolute excess risk is not high with 1.88 excess second 
cancers occurring per 1000 years of patient follow-up. 
Younger age at diagnosis, female gender and certain primary diagnoses, such as hereditary 
retinoblastoma, Hodgkin’s disease and soft tissue sarcomas are associated with an increased 
risk of second cancers. 50 years after diagnosis of hereditary retinoblastoma 51 % of the 
patients have a second cancer. In female Hodgkin’s disease survivors diagnosed and treated 
before 16 years of age between 1955 and 1986, the estimated cumulative probability of 
developing respectively breast and thyroid cancer approached 28% and 6.7% at 30 years from 
diagnosis.  
Radiation-associated risk is highest when the exposure occurs at young age and increases with 
the dose of radiation and increasing follow-up from radiation. Radiation-associated second 
primary cancers include bone tumors, breast cancer, thyroid cancer, brain tumors and basal 
cell carcinoma. 
Exposure to certain chemotherapeutic agents, such as alkylating agents and topoisomerase II 
inhibitors, have been shown to increase the risk of secondary myelodysplasia and acute 
myeloid leukemia, characterized by a short latency period and a finite period of increased 
risk. 
 
Summary 
The late effects of cancer therapy are a significant problem and the risk can be predicted 
based on each individual’s prior therapy. Continued education of cancer survivors regarding 
their risks of late effects is essential and gives them the ability to maintain healthy lifestyles, 
avoiding cancer-promoting behaviors such as smoking. It also gives them the opportunity to 
participate in screening programs to help in early recognition of the late effects. It is hoped 
that the use of early intervention will lead to an improved long-term outcome. Continued 
surveillance of this population is essential. Because the number of childhood cancer survivors 
will continue to increase, it is imperative that pediatricians and internists in the community 
who care for these survivors are aware of their risks for late effects so that they have access to 
and can benefit from early intervention.  
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